Skip to main content
Fig. 4 | Molecular Medicine

Fig. 4

From: Insulin-like Growth Factor I and Urokinase-type Plasminogen Activator Bioregulation System as a Survival Mechanism of Prostate Cancer Cells in Osteoblastic Metastases: Development of Anti-Survival Factor Therapy for Hormone-Refractory Prostate Cancer

Fig. 4

Patient with stage C prostate cancer response to androgen blockade.

The response (as presented by the follow-up of PSA values) in a patient with stage C prostate cancer who was treated with complete androgen blockade (CAB) (GnRH-A; triptorelin 3,75 mg i.m. q28D, plus flutamide 250 mg tid, p.o.) for 30 months before progressing to stage D3 hormone refractory prostate cancer with concurrent development of multiple osteoblastic bone metastases. Anti-androgen (flutamide) withdrawal (AW) did not produce a clinical response and administration of estramustine phosphate (E) 3 × 140 mg tid, p.o., in combination with GnRH-A also failed to arrest disease progression. The patient received combination therapy using anti-survival factor therapy [(ASF) dexamethasone 4 mg, p.o. qD, tapered to 2 mg qD within 3 months and somatostatin analog (lanreotide 30 mg i.m. q14D)] while continuing on GnRH-A (triptorelin, 3,75 mg i.m. q28D). This patient experienced a partial clinical response (decrease of PSA more than 50% and significant improvement of clinical symptoms-pain and analgesics consumption). GnRH, gonadotropin releasing hormone; PSA, prostate-specific antigen.

Back to article page